FDA’s warning letters cite firms over inadequate testing, BIMO violations
Regulatory NewsJoanne S. Eglovitch
CBERCDERComplianceGMPManufacturingOTCPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)Warning letters